Currently, the 1st Resistance Point for this stock is $28.70, with a 2nd Resistance Point sitting at $28.98. Meanwhile, this company’s stock has a 1st Support Level at $28.07 and a 2nd Support Level at $27.72. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Allogene Therapeutics, Inc. (ALLO) was $28.41. Allogene Therapeutics, Inc. (ALLO) stock has gained $1.97, or 2.93%, in the past five days. In the last full month, these shares have lost -$0.53, or -1.83%. In the past three months, this stock’s price has risen by $2.26, or 8.64%. This year-to-date, Allogene Therapeutics, Inc. (ALLO) shares have gained $1.48, or 5.50%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Allogene Therapeutics, Inc. (ALLO) stock, 50% of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Buy .”
With 121,902 K shares outstanding, this company currently has a market capitalization of $3,448,608K. Allogene Therapeutics, Inc. (ALLO) generates annual net income of -$211,510 K. This stock has generated a 1-Year Total Return of -10.35%, a 3-Year Total Return of 0.00%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Allogene Therapeutics, Inc. (ALLO) reported earnings of -$0.50 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.54 per share, representing a 0.04 difference and 7.41% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.41 represented a 0.06 difference from the consensus estimate calling for -$0.47 per share, which was a 12.77% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.69 per share. This estimate came from a total of 9 Wall Street Analysts. Of those market experts, the high estimate was -$0.53 and the low estimate was -$0.79. In the year-ago quarter, Allogene Therapeutics, Inc. (ALLO) generated per-share earnings of -$0.35. If the analysts are correct about the current quarter’s earnings, the growth will be -97.14%.
Turning our focus now to insider trading activity, there have been 15 purchases (156,867 shares in total) and 4 sale (495,450 shares in total) in the last 3 months. In the last 6 months, there have been 28 insider buys amounting to 420,568 shares and 7 insider sales amounting to 544,277 shares. In the past full year, 34 insider purchases were made (involving 752,352 shares) and 12 insider sell-offs equivalent to 3,709,732 shares.
Moving onto liquidity, Allogene Therapeutics, Inc. (ALLO) has a Current Ratio of 15.89, a Quick Ratio of 15.89 and a Cash Ratio of 15.59. Looking at this company’s capital structure, its Total Debt to Total Equity is 4.90, its Total Debt to Total Assets is now 4.45. Looking even further ahead into the future, its Long-Term Debt to Equity is -24.84 and its Long-Term Debt to Total Capital is 4.90.